BVCA Healthcare Sector Digital Forum

Sharon Lamb focuses her practice on transactional and regulatory advice in the health and life sciences sector and leads McDermott’s UK Health and Life Sciences Practice Group.

Sharon advises on global transactional mandates, including mergers and acquisitions and joint ventures in health services, pharma and life sciences, digital health and health technologies. Sharon also provides strategic, regulatory and commercial support to UK and international clients on UK health and life sciences with a focus on health services, pharmaceuticals, medical devices, digital health and health data.

Sharon is widely recognized for her expertise on NHS and public law procurement, regulatory and contracting matters, including payment and reimbursement and market access. She has particular experience advising strategic and private equity investors in transactions and investments in health and life sciences.

Sharon is also well-versed in health care services governance and regulatory matters, NHS public private partnerships, procurements, joint ventures and shared working arrangements, mergers, acquisitions, health data and competition issues.

Sharon has practiced health and life sciences law in the UK since 2002 and is recognized in Chambers and Legal 500. Sharon has written and lectures widely on health and life sciences issues and has a wealth of experience with NHS law and policy, having worked on a 4-year part time secondment with the NHS and national health bodies in London.

Eleanor (Ellie) West centres her practice on private equity transactions and mergers and acquisitions.  Ellie works across a wide range of sectors, and has particular expertise in the health care and life sciences industries.

Ellie regularly advises domestic and international private equity sponsors on transactional matters (including leveraged buy-outs, growth capital investments, add-on acquisitions and the implementation of management incentive plans).  She also advises a range of multi-national corporations on cross-border acquisitions, disposals and restructuring transactions.